[go: up one dir, main page]

BG63152B1 - Дозирани форми с контролирано освобождаване на азитромицин - Google Patents

Дозирани форми с контролирано освобождаване на азитромицин Download PDF

Info

Publication number
BG63152B1
BG63152B1 BG100960A BG10096096A BG63152B1 BG 63152 B1 BG63152 B1 BG 63152B1 BG 100960 A BG100960 A BG 100960A BG 10096096 A BG10096096 A BG 10096096A BG 63152 B1 BG63152 B1 BG 63152B1
Authority
BG
Bulgaria
Prior art keywords
azithromycin
dosage form
membrane
tablet
coating
Prior art date
Application number
BG100960A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG100960A (bg
Inventor
William Curatolo
Hylar Friedman
Richard Korsmeyer
Mott Steven Le
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22900590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG63152(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG100960A publication Critical patent/BG100960A/xx
Publication of BG63152B1 publication Critical patent/BG63152B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)
BG100960A 1994-05-06 1996-11-05 Дозирани форми с контролирано освобождаване на азитромицин BG63152B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23909494A 1994-05-06 1994-05-06
PCT/IB1995/000264 WO1995030422A1 (en) 1994-05-06 1995-04-13 Controlled-release dosage forms of azithromycin

Publications (2)

Publication Number Publication Date
BG100960A BG100960A (bg) 1997-08-29
BG63152B1 true BG63152B1 (bg) 2001-05-31

Family

ID=22900590

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100960A BG63152B1 (bg) 1994-05-06 1996-11-05 Дозирани форми с контролирано освобождаване на азитромицин

Country Status (42)

Country Link
US (2) US6068859A (is)
EP (1) EP0758244B2 (is)
JP (1) JP2977907B2 (is)
KR (1) KR100232297B1 (is)
CN (1) CN1096862C (is)
AP (1) AP548A (is)
AT (1) ATE209497T1 (is)
AU (1) AU680356B2 (is)
BG (1) BG63152B1 (is)
BR (1) BR9501929A (is)
CA (1) CA2189658C (is)
CO (1) CO4290346A1 (is)
CZ (1) CZ292360B6 (is)
DE (1) DE69524214T3 (is)
DK (1) DK0758244T4 (is)
DZ (1) DZ1880A1 (is)
ES (1) ES2163504T5 (is)
FI (1) FI964452A7 (is)
HR (1) HRP950277B1 (is)
HU (1) HUT77530A (is)
IL (3) IL113516A (is)
IS (1) IS4282A (is)
LV (1) LV11729B (is)
MA (1) MA23537A1 (is)
MX (1) MX9605419A (is)
MY (1) MY113059A (is)
NO (1) NO315453B1 (is)
NZ (1) NZ283160A (is)
OA (1) OA10320A (is)
PE (1) PE4796A1 (is)
PL (1) PL179910B1 (is)
PT (1) PT758244E (is)
RO (1) RO114740B1 (is)
RU (1) RU2130311C1 (is)
SI (1) SI9520049A (is)
SK (1) SK282854B6 (is)
TN (1) TNSN95051A1 (is)
TW (1) TW420616B (is)
UA (1) UA41995C2 (is)
UY (1) UY23958A1 (is)
WO (1) WO1995030422A1 (is)
ZA (1) ZA953627B (is)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
PL179910B1 (pl) * 1994-05-06 2000-11-30 Pfizer Postac dawkowania o kontrolowanym uwalnianiu zawierajaca azytromycyne PL PL PL PL PL PL PL PL
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
CA2271569C (en) * 1996-11-15 2003-01-28 Gary Lee Manring Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20040028735A1 (en) * 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
TR200002771T2 (tr) * 1998-03-26 2001-02-21 Fujisawa Pharmaceutical Co.,Ltd. Devamlı salımı olan preparatlar
ATE277594T1 (de) * 1998-06-03 2004-10-15 Alza Corp Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
EP1126827A2 (en) * 1998-11-02 2001-08-29 Alza Corporation Controlled delivery of active agents
DE19850445A1 (de) * 1998-11-02 2000-05-04 Falk Pharma Gmbh Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE404178T1 (de) * 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
US6878386B1 (en) * 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
JP2003508420A (ja) * 1999-09-02 2003-03-04 ノストラム・ファーマスーティカルズ・インコーポレイテッド 経口投与に適した、制御された放出の経口用量
NZ519485A (en) * 1999-12-09 2004-02-27 Boots Co Plc Compressed tablet composition comprising a solidified melt granule of NSAID and silicon dioxide as an extra granular component
WO2001047498A2 (en) 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
GEP20043334B (en) * 1999-12-23 2004-03-10 Pfizer Prod Inc Hydrogel-Driven Drug Dosage Form
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20050175959A1 (en) * 2000-03-14 2005-08-11 Coll Partners Ltd. System for the controlled delivery of an active material to a dental site
IL135061A0 (en) * 2000-03-14 2001-05-20 Ahron Jodaikin Strategic targeted fluoridation and chemical treatment of teeth
US6569152B2 (en) 2000-03-21 2003-05-27 Farrington Pharmaceuticals, Llc Sustained release delivery systems for solutes
FR2811571B1 (fr) * 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
FR2821745B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
AU2002248792B2 (en) * 2001-04-18 2006-09-21 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1652851A1 (en) 2001-05-22 2006-05-03 Pfizer Products Inc. New crystal form of Azithromycin
US20080305173A1 (en) * 2001-07-31 2008-12-11 Beuford Arlie Bogue Amorphous drug beads
BR0211830A (pt) * 2001-08-21 2004-09-08 Pfizer Prod Inc Dose única de azitromicina
WO2003017981A1 (en) * 2001-08-29 2003-03-06 Ranbaxy Laboratories Limited Controlled release formulation of clarithromycin or tinidazol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030152624A1 (en) * 2001-12-20 2003-08-14 Aldrich Dale S. Controlled release dosage form having improved drug release properties
IL161996A0 (en) * 2001-12-21 2005-11-20 Pfizer Prod Inc Directly compressible formulations of azithromycin
PL371125A1 (en) * 2001-12-21 2005-06-13 Pfizer Products Inc. Methods for wet granulating azithromycin
RU2212242C1 (ru) * 2001-12-24 2003-09-20 Закрытое акционерное общество "Брынцалов-А" Антибиотик сумазид
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
EP1478347A1 (en) * 2002-02-01 2004-11-24 Pfizer Products Inc. Dry granulated formulations of azithromycin
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
EP1469833B1 (en) 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
PL371593A1 (en) * 2002-02-01 2005-06-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
ES2314227T7 (es) * 2002-04-09 2012-11-19 Flamel Technologies Formulacion farmaceutica oral en forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de amoxilicina.
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
RU2283116C2 (ru) * 2002-05-27 2006-09-10 Курский государственный медицинский университет Способ увеличения выживаемости изолированного кожного лоскута "на ножке" у животных с пониженным антиоксидантным фоном
WO2003105810A1 (en) * 2002-06-14 2003-12-24 Andrx Corporation Pharmaceutical compositions for drugs having ph-dependentsolubility
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
GB0214013D0 (en) * 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
CA2501324A1 (en) * 2002-10-30 2004-05-21 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
US7811605B2 (en) * 2002-11-06 2010-10-12 Uluru Inc. Method of formation of shape-retentive aggregates of gel particles and their uses
US7351430B2 (en) * 2002-11-06 2008-04-01 Uluru Inc. Shape-retentive hydrogel particle aggregates and their uses
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
NZ540664A (en) 2002-12-16 2007-09-28 Kissei Pharmaceutical Solid drug for oral use
EP1589951B1 (en) 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
FR2850577B1 (fr) * 2003-02-03 2005-04-15 Ethypharm Sa Particules enrobees a gout masque, leur procede de preparation et comprimes orodispersibles contenant lesdites particules
RU2241985C1 (ru) * 2003-03-27 2004-12-10 Томский политехнический университет Способ количественного определения азитромицина дигидрата методом инверсионной вольтамперометрии
JP2006528689A (ja) * 2003-05-06 2006-12-21 ムルイェ、ニルマル エリスロマイシン誘導体の徐放製剤
US7063862B2 (en) 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
EP1638529B1 (en) * 2003-06-16 2016-08-10 ANDRX Pharmaceuticals, LLC. Oral extended-release composition
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2005041838A (ja) * 2003-07-24 2005-02-17 Matsumoto Shika Univ バイオフィルム除去剤
US20050025829A1 (en) * 2003-07-29 2005-02-03 Kim Cherng-Ju Controlled drug release tablets
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
WO2005016278A2 (en) 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
JP5686494B2 (ja) 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
AR046811A1 (es) * 2003-09-02 2005-12-28 Imran Ahmed Formas de dosificacion oral de ziprasidona de liberacion sostenida
AU2004273830B2 (en) 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
KR20080064209A (ko) * 2003-12-04 2008-07-08 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
EP1689368B1 (en) * 2003-12-04 2016-09-28 Bend Research, Inc Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions
RU2006119453A (ru) * 2003-12-04 2007-12-20 Пфайзер Продактс Инк. (Us) Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
CA2547597A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
PL1691787T3 (pl) * 2003-12-04 2008-11-28 Pfizer Prod Inc Sposób wytwarzania farmaceutycznych systemów wielocząstkowych
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053654A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release dosage forms of azithromycin
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
WO2005120585A1 (en) * 2004-06-04 2005-12-22 Case Western Reserve University Dual function polymer micelles
CA2569961A1 (en) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc Controlled release pharmaceutical formulation
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP1771158A4 (en) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSE DISTRIBUTION
ES2582942T3 (es) * 2004-10-08 2016-09-16 Forward Pharma A/S Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
JP2008524317A (ja) * 2004-12-21 2008-07-10 ファイザー・プロダクツ・インク 腸溶コーティングされたアジスロマイシン多粒子
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
WO2007008305A1 (en) * 2005-07-08 2007-01-18 Cherng-Ju Kim Asymmetrically coated tablet
US8858993B2 (en) * 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
EP1749519A1 (de) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
WO2007073596A1 (en) * 2005-12-27 2007-07-05 Labopharm Inc. Degradable polymeric microsphere composition
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US20070243248A1 (en) * 2006-04-14 2007-10-18 Cherukuri S Rao Rapidly disintegrating solid oral dosage form of liquid dispersions
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2007143507A2 (en) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted erythromycin analogs
US7713549B2 (en) * 2006-06-30 2010-05-11 Board Of Trustees Of The University Of Arkansas Extended release perforated tablet
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7910135B2 (en) * 2006-10-13 2011-03-22 Uluru Inc. Hydrogel wound dressing and biomaterials formed in situ and their uses
US20110052688A1 (en) * 2006-11-21 2011-03-03 San-Laung Chow Solid dispersion composition
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
WO2008065504A1 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
CN100441196C (zh) * 2006-12-15 2008-12-10 北京化工大学 一种制备微粉化阿奇霉素的方法
CA2677076C (en) * 2007-03-02 2017-09-12 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
US20080228268A1 (en) * 2007-03-15 2008-09-18 Uluru, Inc. Method of Formation of Viscous, Shape Conforming Gels and Their Uses as Medical Prosthesis
BRPI0700969A (pt) * 2007-03-22 2008-11-04 Ouro Fino Participacoes E Empr composição para o tratamento de afecções bacterianas e inflamatórias em animais de companhia
US7850453B2 (en) * 2007-08-08 2010-12-14 Coll Partners Ltd. Reshapable device for fixation at a dental site
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
EP2187934A1 (en) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of fertirelin and delta-endorphin as therapeutic agents
EP2197467A2 (en) 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis
JP2010538997A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 肺炎連鎖球菌感染の治療における治療剤としての、フィブリノゲン受容体アンタゴニストおよび／またはゴナドトロピン放出ペプチドの使用
EP2188016B1 (en) 2007-09-11 2012-08-01 Mondobiotech Laboratories AG Use of octreotide as a therapeutic agent
WO2009033732A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
JP2010539065A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのペプチドの使用
EP2187916A2 (en) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of gluten exorphin c as a therapeutic agent
WO2009033711A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100190717A1 (en) 2007-09-11 2010-07-29 Dorian Bevec Use of melanin concentrating hormone and met-enkephalin as therapeutic agents
AU2009207796B2 (en) 2008-01-25 2014-03-27 Grunenthal Gmbh Pharmaceutical dosage form
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
HRP20161307T1 (hr) 2008-05-09 2016-12-02 Grünenthal GmbH Postupak za pripravu praškaste formulacije međuproizvoda i konačni kruti oblik doziranja uz korištenje koraka zgrušavanja raspršivanjem
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
EP2198859A1 (en) * 2008-12-17 2010-06-23 Losan Pharma GmbH Melt-coated pharmaceutical composition with fast release
PE20120631A1 (es) 2009-07-22 2012-06-06 Gruenenthal Chemie Forma de dosificacion resistente a la manipulacion para opioides sensibles a la oxidacion
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
EP2498764B1 (en) 2009-11-09 2017-09-06 Spotlight Technology Partners LLC Fragmented hydrogels
NZ599524A (en) 2009-11-09 2014-04-30 Spotlight Technology Partners Llc Polysaccharide based hydrogels
WO2011113507A2 (en) 2010-03-15 2011-09-22 Ulrich Dietz Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
WO2011125075A2 (en) 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
AR082862A1 (es) 2010-09-02 2013-01-16 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico
AU2012204462A1 (en) 2011-01-05 2013-07-11 Hospira, Inc. Spray drying vancomycin
HRP20171458T1 (hr) 2011-07-29 2017-11-17 Grünenthal GmbH Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka
KR20140053159A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
RU2016119726A (ru) * 2011-08-08 2018-11-02 Апталис Фарма Лтд. Способ проведения теста на растворение твердых композиций, содержащих пищеварительные ферменты
CA2885680C (en) * 2011-09-07 2022-10-04 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal.
US10653631B2 (en) 2011-09-07 2020-05-19 Roland SAUR-BROSCH Optimal colon targeting technology
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
US20130172271A1 (en) * 2012-01-04 2013-07-04 Cynthia Fragale Pharmaceutical Spray Drying
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
EP2885045A4 (en) * 2012-08-20 2016-07-20 O Ray Pharma Inc METHOD FOR MANUFACTURING DRUG DELIVERY FORMULATIONS
CN103860515A (zh) * 2012-12-10 2014-06-18 中国科学院上海药物研究所 阿奇霉素渗透泵控释片及其制备方法
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EA032465B1 (ru) 2013-07-12 2019-05-31 Грюненталь Гмбх Защищенная от применения не по назначению пероральная фармацевтическая лекарственная форма, содержащая этиленвинилацетатный полимер, и способ ее изготовления
US9668844B2 (en) 2013-11-06 2017-06-06 Colldent Y.A Ltd Device for fixation at a dental site
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
WO2015181059A1 (en) 2014-05-26 2015-12-03 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
HK1246173A1 (zh) 2015-04-24 2018-09-07 Grünenthal GmbH 具有立即释放和对溶剂萃取的抗性的抗篡改剂型
WO2016201259A1 (en) * 2015-06-10 2016-12-15 Piedmont Pharmaceuticals Llc Injectable antibiotic formulations and use thereof
WO2017042325A1 (en) 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2018190621A1 (ko) * 2017-04-10 2018-10-18 성균관대학교 산학협력단 다공성 위체류층을 포함하는 서방성 제제 및 이의 제조방법
GB201904757D0 (en) * 2019-04-04 2019-05-22 Biorelevant Com Ltd Biorelevant composition
ES2995086T3 (en) 2019-10-11 2025-02-05 Anatara Lifesciences Ltd Gastrointestinal health composition
CN112326838A (zh) * 2020-11-10 2021-02-05 湖北省宏源药业科技股份有限公司 一种改善阿奇霉素胶囊溶出曲线的测定方法
CN113116859B (zh) * 2021-04-12 2022-08-30 海南普利制药股份有限公司 阿奇霉素丸芯包衣制剂
CN113985783B (zh) * 2021-10-29 2022-09-02 中山东菱威力电器有限公司 一种冰激淋料浆有无检测电路
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
SI8110592A8 (en) * 1981-03-06 1996-06-30 Pliva Pharm & Chem Works Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
PH19293A (en) * 1982-11-15 1986-03-04 Pfizer Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof
US4851231A (en) * 1982-12-13 1989-07-25 Alza Corporation System for delivering drug in selected environment of use
US4496322A (en) 1983-05-11 1985-01-29 University Of Toronto Innovations Foundation Benzoin antimicrobial dental varnishes
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
EP0243302B1 (en) 1986-04-17 1992-01-22 Eltech Systems Corporation An electrode with a platinum metal catalyst in surface film and its use
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
IT1222309B (it) 1987-07-08 1990-09-05 Menarini Sas Utilizzazione di forme farmaceutiche per uso topico contenenti miocamicina per la terapia delle infezione da germi sensibili alla miocamicina stessa
MX12213A (es) * 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US4925674A (en) * 1988-08-25 1990-05-15 Himedics, Inc. Amoxicillin microencapsulated granules
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
IE64761B1 (en) * 1989-02-16 1995-09-06 British Tech Group Dispensing device
DE69023241T2 (de) * 1989-07-18 1996-04-04 Alza Corp Ionophore enthaltende abgabevorrichtung.
US5198220A (en) 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5173299A (en) 1989-11-17 1992-12-22 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5084267A (en) 1989-11-17 1992-01-28 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5230895A (en) 1990-05-01 1993-07-27 Copley Pharmaceutical Inc. Sustained released delivery system for use in the periodontal pocket
EP0528971B1 (en) * 1990-05-14 1999-09-01 JERNBERG, Gary R. Surgical implant and method incorporating chemotherapeutic agents
US5114718A (en) 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
SE9201930D0 (sv) † 1992-06-24 1992-06-24 Astra Ab Gastric antibacterial treatment
TW271400B (is) * 1992-07-30 1996-03-01 Pfizer
EP0670717B1 (en) 1992-11-30 1998-11-25 Pfizer Inc. Supported liquid membrane delivery devices
AU7957994A (en) * 1993-10-01 1995-05-01 Procter & Gamble Company, The Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use
US5605889A (en) † 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
PL179910B1 (pl) * 1994-05-06 2000-11-30 Pfizer Postac dawkowania o kontrolowanym uwalnianiu zawierajaca azytromycyne PL PL PL PL PL PL PL PL
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6984403B2 (en) † 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects

Also Published As

Publication number Publication date
PE4796A1 (es) 1996-03-09
HRP950277B1 (en) 2002-06-30
OA10320A (en) 1997-10-07
MX9605419A (es) 1997-12-31
ZA953627B (en) 1996-11-05
DE69524214D1 (de) 2002-01-10
CA2189658A1 (en) 1995-11-16
CN1096862C (zh) 2002-12-25
DK0758244T3 (da) 2002-02-11
MA23537A1 (fr) 1995-12-31
FI964452A0 (fi) 1996-11-05
FI964452L (fi) 1996-11-05
EP0758244B2 (en) 2008-02-13
NZ283160A (en) 1998-07-28
AU680356B2 (en) 1997-07-24
AP9500735A0 (en) 1995-04-30
CO4290346A1 (es) 1996-04-17
SI9520049A (en) 1997-12-31
AU2113195A (en) 1995-11-29
EP0758244B1 (en) 2001-11-28
PL317106A1 (en) 1997-03-17
DK0758244T4 (da) 2008-06-16
KR100232297B1 (ko) 1999-12-01
US7108865B2 (en) 2006-09-19
TW420616B (en) 2001-02-01
LV11729B (en) 1997-08-20
RU2130311C1 (ru) 1999-05-20
TNSN95051A1 (fr) 1996-02-06
PT758244E (pt) 2002-04-29
HUT77530A (hu) 1998-05-28
HRP950277A2 (en) 1997-10-31
KR970702727A (ko) 1997-06-10
NO315453B1 (no) 2003-09-08
DZ1880A1 (fr) 2002-02-17
FI964452A7 (fi) 1996-11-05
NO964678D0 (no) 1996-11-05
ES2163504T3 (es) 2002-02-01
IL113516A0 (en) 1995-07-31
ATE209497T1 (de) 2001-12-15
DE69524214T3 (de) 2008-05-15
IL131308A0 (en) 2001-01-28
EP0758244A1 (en) 1997-02-19
RO114740B1 (ro) 1999-07-30
CA2189658C (en) 2000-10-31
UY23958A1 (es) 1995-10-31
PL179910B1 (pl) 2000-11-30
US20020044965A1 (en) 2002-04-18
AP548A (en) 1996-10-30
SK282854B6 (sk) 2002-12-03
US6068859A (en) 2000-05-30
DE69524214T2 (de) 2002-05-23
HU9603076D0 (en) 1997-01-28
JP2977907B2 (ja) 1999-11-15
MY113059A (en) 2001-11-30
IL113516A (en) 2001-04-30
LV11729A (lv) 1997-04-20
SK143296A3 (en) 1998-07-08
WO1995030422A1 (en) 1995-11-16
CN1149831A (zh) 1997-05-14
IL131308A (en) 2001-07-24
JPH09505609A (ja) 1997-06-03
CZ292360B6 (cs) 2003-09-17
UA41995C2 (uk) 2001-10-15
BR9501929A (pt) 1996-03-05
BG100960A (bg) 1997-08-29
CZ324296A3 (cs) 1998-04-15
ES2163504T5 (es) 2008-05-16
NO964678L (no) 1997-01-06
IS4282A (is) 1995-11-07

Similar Documents

Publication Publication Date Title
BG63152B1 (bg) Дозирани форми с контролирано освобождаване на азитромицин
CA2342340C (en) New sustained release oral formulations
US5540945A (en) Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
JP2002533380A (ja) 多孔性粒子を含む剤形
JPH03112930A (ja) ミノサイクリンの脈動性１日１回放出系
EP1916995B1 (en) Ph-controlled pulsatile delivery system, methods for preparation and use thereof
CA2032475C (en) Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines
BG64742B1 (bg) Дозирани форми на сертралин със забавено освобождаване
CA2379595A1 (en) Oral controlled release formulations
CZ118899A3 (cs) Kompozice s pozvolným uvolňováním léčiva, způsob přípravy této kompozice, způsob zlepšení profilu uvolňování léčiva a použití této kompozice
Nykänen Development of multiple-unit oral formulations for colon-specific drug delivery using enteric polymers and organic acids as excipients
US20040062799A1 (en) Therapeutic composition and delivery system for administering drug
MXPA01002365A (en) New sustained release oral formulations